Welcome to our dedicated page for Rocket Pharmaceu news (Ticker: RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceu stock.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company developing investigational genetic therapies for rare and often life-threatening disorders. The RCKT news feed on Stock Titan aggregates company announcements, press releases and third-party coverage related to its AAV and lentiviral gene therapy programs.
Investors following Rocket’s news can track updates on its adeno-associated viral (AAV) cardiovascular portfolio, which includes RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM) and RP-A701 for BAG3-associated dilated cardiomyopathy (BAG3-DCM). News items frequently cover clinical trial milestones, such as FDA lifting a clinical hold on the pivotal Phase 2 trial of RP-A501, preliminary Phase 1 data for RP-A601, and IND clearance and Fast Track designation for RP-A701.
The news stream also highlights developments in Rocket’s lentiviral (LV) hematology portfolio, including regulatory progress for KRESLADI (marnetegragene autotemcel; marne-cel) in severe leukocyte adhesion deficiency-I (LAD-I). Articles may discuss FDA acceptance of the resubmitted Biologics License Application (BLA), the setting of a Prescription Drug User Fee Act (PDUFA) target action date, and clinical data showing survival and infection outcomes in treated patients.
Beyond pipeline updates, RCKT news includes financial results, strategic corporate reorganization and pipeline prioritization announcements, leadership and board changes, equity inducement grants and participation in major healthcare investor conferences. By reviewing this page regularly, readers can follow how Rocket’s clinical, regulatory and corporate events may influence sentiment around RCKT stock and gain context on the company’s progress in gene therapy for rare cardiovascular and hematologic diseases.
Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focusing on genetic therapies for rare disorders, has announced its participation in two upcoming investor conferences. The company will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 2:35 PM ET, and the 2024 Cantor Fitzgerald Global Healthcare Conference on September 17, 2024, at 10:55 AM ET.
CEO Gaurav Shah, M.D., will engage in fireside chats at both events, and the management team will host investor meetings. Webcasts of the presentations will be accessible on the Investors section of Rocket Pharmaceuticals' website, providing an opportunity for stakeholders to stay informed about the company's progress and strategies in developing genetic therapies for rare disorders with high unmet needs.
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q2 2024 financial results and pipeline progress. Key highlights include:
- Ongoing enrollment in pivotal Phase 2 study of RP-A501 for Danon disease and Phase 1 study of RP-A601 for PKP2 arrhythmogenic cardiomyopathy
- Presented long-term KRESLADI™ data showing 100% survival rate in LAD-I patients
- Cash position of $278.8M, expected to fund operations into 2026
- R&D expenses decreased to $91.6M from $97.8M in Q2 2023
- G&A expenses increased to $49.5M from $33.2M in Q2 2023
- Net loss of $131.7M or $1.40 per share
The company is preparing for potential FDA approval of KRESLADI for severe LAD-I and advancing its clinical pipeline in rare genetic disorders.
Rocket Pharmaceuticals (NASDAQ: RCKT) has received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application for KRESLADI™ (marnetegragene autotemcel; marne-cel), a gene therapy for severe leukocyte adhesion deficiency-I (LAD-I). The FDA has requested additional Chemistry Manufacturing and Controls (CMC) information. Rocket met with FDA leaders to expedite the approval process. The global Phase 1/2 study showed 100% overall survival at 12 months for all nine patients, with significant reductions in infections and improvements in LAD-I symptoms. KRESLADI™ was well tolerated with no serious adverse events reported.
Rocket Pharmaceuticals (NASDAQ: RCKT) has received orphan medicinal product designation from the European Commission for its gene therapy candidate, RP-A601, aimed at treating plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM). This inherited heart disease affects around 50,000 individuals in the U.S. and Europe, leading to life-threatening arrhythmias and sudden cardiac death. Currently, there are no curative treatments available. The orphan designation provides various financial and regulatory benefits, including a 10-year market exclusivity post-approval. Rocket is conducting a Phase 1 trial to evaluate the safety and preliminary efficacy of RP-A601 in adult PKP2-ACM patients.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) presented positive long-term data updates from its LV vector hematology portfolio at the ASGCT meeting. The data demonstrated sustained safety and efficacy in pivotal studies of KRESLADI™ for severe LAD-I, RP-L102 for Fanconi Anemia, and RP-L301 for PKD. KRESLADI™ showed 100% survival without HSCT, RP-L102 had genetic and phenotypic correction, and RP-L301 had clinically meaningful hemoglobin improvement. The safety profiles were well-tolerated with no drug-related serious adverse events.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported strong financial results for the first quarter of 2024. The company advanced its RP-L102 for Fanconi Anemia towards regulatory reviews, with an anticipated BLA submission in 2024. The EMA accepted the MAA for review. KRESLADI for severe LAD-I is on track for a PDUFA date of June 30, 2024. Aaron Ondrey was appointed as CFO. Rocket's cash, cash equivalents, and investments stood at $330.3M, providing operational runway into 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.